Retinal penetrating AAV
AAV‑IKV is designed for transgene delivery from the vitreous through retinal layers to outer retinal targets, including photoreceptors and RPE.
Retinal penetrating AAV for blinding disease
Delivering genetic medicines to ocular tissues that are difficult to reach.
Visiogene is a preclinical-stage biotechnology startup developing AAV‑IKV, a retinal‑penetrating AAV platform, and Nuc1, a protein and large‑molecule delivery chaperone, for diseases that cause blindness.
Vitreous to outer retinaAAV‑IKV retinal penetration
Decorin biologyFibrosis, CNV, and trabecular meshwork remodeling
Complement modulationUndisclosed dry AMD program
The eye provides local routes for administration, but retinal barriers still determine whether a therapeutic payload reaches photoreceptors, RPE, or outflow tissues.
Research packageScientific focus
A delivery platform organized around defined ocular compartments.
The programs apply engineered delivery to compartments where disease biology is well characterized: the outer retina in macular degeneration and retinal degeneration, and the trabecular meshwork in glaucoma.
Wet AMD and fibrosis
AAV‑IKV‑Decorin studies address laser‑induced CNV and the fibrotic response, rather than treating angiogenesis as the only disease process.
Dry AMD complement
An undisclosed dry AMD program is focused on local complement modulation, building on Visiogene’s experience in complement biology for geographic atrophy.
Glaucoma outflow biology
AAV‑IKV‑Decorin is being studied for TGFβ2‑driven fibrosis at the trabecular meshwork, a mechanism linked to aqueous humor outflow resistance.
Platform emphasis
AAV‑IKV was developed to penetrate the retina from an intravitreal route.
The vector platform addresses a central constraint in ocular gene therapy: outer retinal cells are biologically important targets, but conventional vectors delivered into the vitreous generally have limited access to photoreceptors and RPE.
Read about AAV‑IKVIntravitreal routeVector enters the vitreous
Retinal penetrationMovement across retinal barriers
Outer retinal expressionPhotoreceptors and RPE
AAV‑IKV also provides a delivery framework for anterior segment studies, including intracameral delivery to tissues involved in glaucoma pathophysiology.
Retinal disease program
Wet AMD studies directed at neovascularization and fibrosis.
The wet AMD program uses AAV‑IKV to deliver decorin, a matrix-associated proteoglycan with relevance to angiogenic, fibrotic, inflammatory, and autophagy pathways. The public preclinical work emphasizes both CNV and subretinal fibrosis.
Wet AMD programCNV+vascular leakage biology
Fibrosis+TGFβ-related remodeling
AAV‑IKV‑Decorin→preclinical decorin expression
TGFβ2→EMT and fibrosis
Trabecular meshwork→outflow resistance
Decorin→anti‑fibrotic counter‑biology
Glaucoma program
Local gene delivery to fibrotic outflow tissue.
In glaucoma models, AAV‑IKV is used as the delivery layer and decorin as the therapeutic transgene. Endpoints include trabecular meshwork fibrosis, intraocular pressure, retinal ganglion cell integrity, and ocular tolerability observations.
Glaucoma sciencePipeline
Programs selected for delivery, payload biology, and ocular compartment fit.
AAV‑IKV platform
Retinal penetrating AAV designed to access outer retinal cell types from the vitreous.
View platform →AAV‑IKV‑Decorin
Decorin delivery studied for effects on neovascularization, fibrosis, inflammation, and autophagy.
View program →Undisclosed complement program
Novel local complement targeting for dry AMD, with target and construct details undisclosed.
View program →AAV‑IKV‑Decorin
Anterior segment gene delivery focused on TGFβ2 / decorin biology and trabecular meshwork fibrosis.
View program →Team
Ocular gene therapy, retinal disease models, and clinical perspective.
Visiogene’s team combines ocular genetics, AAV vector development, retinal degeneration model expertise, and clinical research perspective.
TeamRajendra Kumar‑Singh, PhDFounder and CEO
Manish Mishra, PhDSenior Scientist
Tiffany Kolniak, MD, PhDClinical and Research Advisor